KAZA1
MCID: KLZ004
MIFTS: 43

Kala-Azar 1 (KAZA1)

Categories: Infectious diseases, Rare diseases

Aliases & Classifications for Kala-Azar 1

MalaCards integrated aliases for Kala-Azar 1:

Name: Kala-Azar 1 57
Kala-Azar, Susceptibility to, 1 57 13
Leishmaniasis 59 72
Leishmaniasis, Visceral, Susceptibility to, 1 57
Leishmaniasis, Visceral 1 57
Kaza1 57

Characteristics:

Orphanet epidemiological data:

59
leishmaniasis
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-5/10000 (Worldwide); Age of onset: All ages;

Classifications:

Orphanet: 59  
Rare infectious diseases


External Ids:

MESH via Orphanet 45 D007896
ICD10 via Orphanet 34 B55.0 B55.1 B55.2 more
UMLS via Orphanet 73 C0023281
Orphanet 59 ORPHA507
UMLS 72 C0023281

Summaries for Kala-Azar 1

MalaCards based summary : Kala-Azar 1, also known as kala-azar, susceptibility to, 1, is related to cutaneous leishmaniasis and visceral leishmaniasis, and has symptoms including fever, pruritus and exanthema. An important gene associated with Kala-Azar 1 is KAZA1 (Kala-Azar (Visceral Leishmaniasis), Susceptibility To). The drugs Lidocaine and Amphotericin B have been mentioned in the context of this disorder. Affiliated tissues include testes, t cells and skin, and related phenotypes are splenomegaly and hepatomegaly

More information from OMIM: 608207 PS608207

Related Diseases for Kala-Azar 1

Diseases in the Kala-Azar 1 family:

Kala-Azar 2 Kala-Azar 3

Diseases related to Kala-Azar 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 594)
# Related Disease Score Top Affiliating Genes
1 cutaneous leishmaniasis 13.0
2 visceral leishmaniasis 12.9
3 mucocutaneous leishmaniasis 12.9
4 leishmaniasis, tegumentary 12.4
5 kala-azar 2 11.7
6 kala-azar 3 11.7
7 chronic rhinitis 11.5
8 leishmaniasis 11.4
9 splenomegaly 10.9
10 pancytopenia 10.8
11 chagas disease 10.8
12 hansen's disease 10.7
13 leprosy 3 10.7
14 immune deficiency disease 10.6
15 skin disease 10.6
16 acquired immunodeficiency syndrome 10.6
17 trypanosomiasis 10.6
18 cytokine deficiency 10.5
19 human immunodeficiency virus type 1 10.5
20 triiodothyronine receptor auxiliary protein 10.5
21 neutropenia 10.5
22 allergic hypersensitivity disease 10.5
23 malaria 10.5
24 thrombocytopenia 10.5
25 sleeping sickness 10.4
26 schistosoma mansoni infection, susceptibility/ 10.4
27 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.4
28 schistosomiasis 10.4
29 toxoplasmosis 10.4
30 diarrhea 10.4
31 hemophagocytic lymphohistiocytosis 10.4
32 bacterial infectious disease 10.4
33 exanthem 10.4
34 lupus erythematosus 10.4
35 erysipeloid 10.3
36 autoimmune disease 10.3
37 glomerulonephritis 10.3
38 systemic lupus erythematosus 10.3
39 lepromatous leprosy 10.3
40 sporotrichosis 10.3
41 pulmonary tuberculosis 10.3
42 47,xyy 10.3
43 filariasis 10.3
44 uveitis 10.3
45 acute kidney failure 10.3
46 kidney disease 10.3
47 vasculitis 10.3
48 alopecia 10.3
49 gastrointestinal ulceration, recurrent, with dysfunctional platelets 10.2
50 lymphopenia 10.2

Graphical network of the top 20 diseases related to Kala-Azar 1:



Diseases related to Kala-Azar 1

Symptoms & Phenotypes for Kala-Azar 1

Human phenotypes related to Kala-Azar 1:

59 (show all 25)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 splenomegaly 59 Very frequent (99-80%)
2 hepatomegaly 59 Very frequent (99-80%)
3 fatigue 59 Occasional (29-5%)
4 arthralgia 59 Frequent (79-30%)
5 anemia 59 Frequent (79-30%)
6 pancytopenia 59 Very frequent (99-80%)
7 pallor 59 Frequent (79-30%)
8 abnormal bleeding 59 Very frequent (99-80%)
9 papule 59 Very frequent (99-80%)
10 skin ulcer 59 Very frequent (99-80%)
11 weight loss 59 Frequent (79-30%)
12 elevated hepatic transaminase 59 Frequent (79-30%)
13 thrombocytopenia 59 Occasional (29-5%)
14 anorexia 59 Occasional (29-5%)
15 episodic fever 59 Very frequent (99-80%)
16 lymphadenopathy 59 Very frequent (99-80%)
17 abnormality of oral mucosa 59 Very frequent (99-80%)
18 increased antibody level in blood 59 Frequent (79-30%)
19 leukopenia 59 Occasional (29-5%)
20 rhinitis 59 Very frequent (99-80%)
21 abnormality of the oral cavity 59 Very frequent (99-80%)
22 skin plaque 59 Very frequent (99-80%)
23 hypoalbuminemia 59 Frequent (79-30%)
24 abnormality of macrophages 59 Very frequent (99-80%)
25 night sweats 59 Very frequent (99-80%)

Clinical features from OMIM:

608207

UMLS symptoms related to Kala-Azar 1:


fever, pruritus, exanthema

Drugs & Therapeutics for Kala-Azar 1

Drugs for Kala-Azar 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 121)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
2
Amphotericin B Approved, Investigational Phase 4 1397-89-3 14956 5280965
3
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
4
Dimethyl sulfoxide Approved, Vet_approved Phase 4 67-68-5 679
5
deoxycholic acid Approved Phase 4 83-44-3 222528
6
meglumine antimoniate Experimental, Investigational Phase 4 133-51-7
7 Anesthetics Phase 4
8 Antifungal Agents Phase 4
9 Liposomal amphotericin B Phase 4
10 Anti-Infective Agents Phase 4
11 Antiparasitic Agents Phase 4
12 Anti-Bacterial Agents Phase 4
13 Antiprotozoal Agents Phase 4
14 Free Radical Scavengers Phase 4
15 Antioxidants Phase 4
16 Gastrointestinal Agents Phase 4
17 Amphotericin B, deoxycholate drug combination Phase 4
18 Cholagogues and Choleretics Phase 4
19
Pentoxifylline Approved, Investigational Phase 2, Phase 3 6493-05-6 4740
20
Imiquimod Approved, Investigational Phase 3 99011-02-6 57469
21
carbamide peroxide Approved Phase 2, Phase 3 124-43-6
22
Pentamidine Approved, Investigational Phase 2, Phase 3 100-33-4 4735
23
Aluminum sulfate Approved Phase 2, Phase 3 10043-01-3
24
Zinc Approved, Investigational Phase 2, Phase 3 7440-66-6 32051
25
Tocopherol Approved, Investigational Phase 3 1406-66-2, 54-28-4 14986
26
Zinc sulfate Approved, Investigational Phase 2, Phase 3 7733-02-0
27
Paromomycin Approved, Investigational Phase 2, Phase 3 7542-37-2, 1263-89-4 165580
28
Miltefosine Approved, Investigational Phase 3 58066-85-6 3600
29
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
30
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
31
Azithromycin Approved Phase 2, Phase 3 83905-01-5 447043 55185
32
Nitric Oxide Approved Phase 3 10102-43-9 145068
33
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
34 Tocotrienol Investigational Phase 3 6829-55-6
35 Vaccines Phase 2, Phase 3
36 Phosphodiesterase Inhibitors Phase 2, Phase 3
37 Radiation-Protective Agents Phase 2, Phase 3
38 Platelet Aggregation Inhibitors Phase 2, Phase 3
39 Adjuvants, Immunologic Phase 3
40 interferons Phase 3
41 Interferon Inducers Phase 3
42 Vitamins Phase 3
43 Nutrients Phase 2, Phase 3
44 Micronutrients Phase 2, Phase 3
45 Trace Elements Phase 2, Phase 3
46 Tocotrienols Phase 3
47 Tocopherols Phase 3
48 Dermatologic Agents Phase 2, Phase 3
49 Astringents Phase 2, Phase 3
50 Anthelmintics Phase 3

Interventional clinical trials:

(show top 50) (show all 165)
# Name Status NCT ID Phase Drugs
1 Point of Care Diagnosis and Treatment With Single Dose Liposomal Amphotericin B for Visceral Leishmaniasis in India. Unknown status NCT01566552 Phase 4 AMBISOME
2 Efficacy and Safety of Amphotericin B Deoxycholate Compared to Meglumine Antimoniate for Treatment of Visceral Leishmaniasis in Brazilian Children Completed NCT01032187 Phase 4 Meglumine antimoniate;Amphotericin B-deoxycholate
3 Low-dose Pentavalent Antimony Treatment of Cutaneous Leishmaniasis in Old Age Patients Infected With Leishmania (Viannia) Braziliensis in Bahia State, Brazil. An Open Uncontrolled Trial. Completed NCT00818818 Phase 4 Meglumine antimoniate
4 Pharmacokinetics of Miltefosine in Children and Adults: Implications for the Treatment of Cutaneous Leishmaniasis in Colombia. Completed NCT01462500 Phase 4 Miltefosine
5 Safety and Effectiveness of Short-course AmBisome in the Treatment of Post-Kala-azar Dermal Leishmaniasis (PKDL): a Prospective Cohort Study in Bangladesh Completed NCT03311607 Phase 4 AmBisome
6 Phase IV Randomized Controlled Clinical Trial to Evaluate the Safety and Efficacy of Low-Dose Pentavalent Antimony Compared to the Standard Dose in Patients With Cutaneous Leishmaniasis Caused by Leishmania (Viannia)Braziliensis Completed NCT00317980 Phase 4 Meglumine antimoniate;Meglumine antimoniate
7 A Phase 4 Study to Expand Access Program While Assessing the Safety and Efficacy of Paromomycin IM Injection in an Outpatient Setting for the Treatment of Visceral Leishmaniasis Completed NCT00604955 Phase 4 Paromomycin sulfate
8 A Study to Explore Association of Treatment Regimens for Visceral Leishmaniasis, Host Immunological, Genetical and Nutrition Factors With Post-kala-azar Dermal Leishmaniasis (PKDL) Completed NCT01975051 Phase 4 Mitefosine
9 An Open Label Study of RFH Therapy as Treatment for CL Caused by Leishmania Tropica in India Completed NCT01661296 Phase 4 Sodium stibogluconate
10 Comparison of Effectiveness of Topical Amphotericin B in 30% Dimethylsulphoxide and 30% Dimethylsulphoxide in Treating of Non-dermatophytes Onychomycosis: Randomized Double Blind Controlled Trial Pilot Study Recruiting NCT03814343 Phase 4 amphotericin B in 30% DMSO;30% DMSO
11 Multicentric Efficacy and Safety Study of Antileishmanial Drugs for Treatment of Visceral Leishmaniasis in Brazil Terminated NCT01310738 Phase 4 Antimoniate of N-methylglucamine;amphotericin B deoxycholate;Liposomal amphotericin B;Liposomal amphotericin B;Antimoniate of N-methylglucamine
12 Randomized Clinical Trial of the Efficacy and Tolerability of Oral Miltefosine Versus Parenteral Antimony for the Treatment of Pediatric Cutaneous Leishmaniasis in Colombia Unknown status NCT00487253 Phase 3 Miltefosine;Meglumine antimoniate
13 Randomized, Open-label, Parallel-group, Safety & Efficacy Study to Evaluate Different Combination Treatment Regimens, of Either AmBisome and Paromomycin, AmBisome and Miltefosine, or Paromomycin and Miltefosine Compared With Amphotericin B Deoxycholate (the Standard) Therapy for the Treatment of Acute, Symptomatic Visceral Leishmaniasis (VL). Completed NCT00696969 Phase 3 Amphotericin B Deoxycholate;Ambisome + Miltefosine;Ambisome and Paromomycin;Miltefosine and Paromomycin
14 A Phase 3 Multicenter, Randomized, Controlled, Clinical Trial to Assess the Safety and Efficacy of Injectable Paromomycin in Patients With Visceral Leishmaniasis Completed NCT00216346 Phase 3 Paromomycin sulfate;Amphotericin B
15 Double-blind Placebo Controlled Trial Using Pentoxifylline Associated With Pentavalent Antimony in Cutaneous Leishmaniasis Completed NCT01381055 Phase 2, Phase 3 Pentoxifylline;Placebo
16 Randomized Double Blind Clinical Trial of Imiquimod (Aldara) Versus Placebo Used in Combination With Pentavalent Antimony (Glucantime) in Peruvian Cutaneous Leishmaniasis Patients Completed NCT00257530 Phase 3 Imiquimod
17 Topical Paromomycin Cream For Bolivian Cutaneous Eishmaniasis: A Controlled Study Completed NCT03096457 Phase 2, Phase 3 Paromomycin Sulfate;Pentamidine Isethionate
18 A Prospective, Multicentric, Randomized, Two Arm, Open Label Phase III Study To Assess Efficacy And Safety Of Infusion Of Amphomul® (Amphotericin B Emulsion) As Compared To Liposomal Amphotericin In Patients Of Visceral Leishmaniasis (Kala Azar) Completed NCT00876824 Phase 3 Amphotericin B Lipid emulsion;Liposomal Amphotericin B
19 Phase 2 Study Electrothermocauterisation of Afghan Patients With Anthroponotic Cutaneous Leishmaniasis With and Without Pharmaceutical Chlorite Listed in the German Drug Codex (DAC N-055) Completed NCT00947362 Phase 2, Phase 3 DAC N-055;saline
20 A Phase III Randomized, Controlled, Clinical Trial to Assess the Safety and Efficacy of Single Infusion of Liposomal Amphotericin B in Patients With Visceral Leishmaniasis Completed NCT00628719 Phase 3 Liposomal Amphotericin B;amphotericin B deoxycholate
21 Efficacy Study of Liposomal Amphotericin in Disseminated Leishmaniasis Completed NCT02025491 Phase 3 Liposomal Amphotericin B
22 A Pivotal, Randomized, Double-blind, Vehicle-controlled Study to Evaluate WR 279,396 and Paromomycin Alone to Treat Cutaneous Leishmaniasis (in Tunisia) Completed NCT00606580 Phase 3 WR 279,396 topical cream;Paromomycin Alone topical cream;Vehicle placebo cream
23 Therapeutic Gain of Adding the Immunomodulator Pentoxifylline to the Treatment of Cutaneous Leishmaniasis Completed NCT01464242 Phase 2, Phase 3 Meglumine antimonate;Placebo;Pentoxifylline
24 A Multicentre Comparative Trial of Efficacy and Safety of Sodium Stibogluconate (SSG) Versus Paromomycin (PM) Versus Combination of SSG and PM as the First Line Treatment for Visceral Leishmaniasis in Ethiopia, Kenya and Sudan Completed NCT00255567 Phase 3 Sodium Stibogluconate;Paromomycin sulphate;SSG and Paromomycin sulphate
25 A Randomized, Double-blind, Pivotal Phase 3 Study of WR 279,396 (Paromomycin + Gentamicin Topical Cream) and Paromomycin Alone Topical Cream for the Treatment of Cutaneous Leishmaniasis in Panama Completed NCT01790659 Phase 3 WR 279,396;Paromomycin
26 An Open Lable Randomised Two -Arm Study to Assess the Safety and Efficacy of Paromomycin Administered Intramuscularly at Two Different Dosing Regimens (14 Days Versus 21 Days) for the Treatment of Indian Visceral Leishmaniasis (VL) Completed NCT00629031 Phase 3 Paromomycin;Paromomycin
27 A Randomized, Safety, Immunogenicity & Efficacy Study of Autoclaved Leishmania Major Plus BCG vs. BCG (Double Blind) or Placebo (Open), in Healthy High Risk Iranian Volunteers With Positive Response to Leishmanin (LST>0) Completed NCT00429780 Phase 2, Phase 3
28 A Phase III, Open Label, Randomised, Study of Three Short Course Combination Regimens (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome® Alone for the Treatment of Visceral Leishmaniasis (VL) in Bangladesh Completed NCT01122771 Phase 3 Liposomal amphotericin B;liposomal amphotericin B + miltefosine;liposomal amphotericin B + paromomycin;Miltefosine + Paromomycin
29 Phase 3, Clinical Trials of Drug Against Cutaneous Leishmaniasis Completed NCT00351520 Phase 3 Miltefose
30 A Randomised, Open-label, Parallel-group, Safety and Efficacy Study to Evaluate Different Combination Treatment Regimens (Co-administration), of AmBisome, Paromomycin and Miltefosine in Visceral Leishmaniasis (VL) Completed NCT00523965 Phase 3 amphotericin B deoxycholate;Liposomal Amphotericin B with Miltefosine;Liposomal Amphotericin B and Paromomycin Sulfate;miltefosine + Paromomycin sulfate
31 A Randomized Trial of Ambisome Monotherapy and Combination of Ambisome and Miltefosine for the Treatment of VL in HIV Positive Patients in Ethiopia Followed by Secondary VL Prophylactic Treatment With Pentamidine. Completed NCT02011958 Phase 3 Liposomal Amphotericin B;Miltefosine
32 Phase III Clinical Trial for American Tegumentary Leishmaniasis: Comparison of Standard and Alternative Antimonial Dosage in Patients With American Cutaneous Leishmaniasis Completed NCT01301924 Phase 2, Phase 3 Meglumine antimoniate
33 A Study for Safety and Efficacy of Miltefosine for Treatment of Children and Adolescents With Post-Kala-azar Dermal Leishmaniasis (PKDL) in Bangladesh and Association of Serum Vitamin E and Exposure to Arsenic With PKDL Completed NCT02193022 Phase 3 Miltefosine
34 Phase 3 Open-label Study of Efficacy and Safety of Miltefosine or Thermotherapy vs Glucantime for Cutaneous Leishmaniasis in Colombia. Completed NCT00471705 Phase 3 Miltefosine;Glucantime®
35 A Randomized, Safety, Immunogenicity & Efficacy Study of Autoclaved Leishmania Major Plus BCG vs. BCG (Double Blind) or Placebo (Open), in Healthy High Risk Iranian Volunteers With no Response to Leishmanin Completed NCT00429715 Phase 2, Phase 3
36 Secondary Prophylaxis of Visceral Leishmaniasis Relapses in HIV Co-infected Patients Using Pentamidine as a Prophylactic Agent: a Prospective Cohort Study Completed NCT01360762 Phase 3 Pentamidine
37 Replacement of Insecticides to Control Visceral Leishmaniasis Completed NCT01644682 Phase 3
38 A Randomized, Double Blind, Controlled Study to Determine the Efficacy of Zinc Supplementation on Diarrhea Incidence in an Adult Population in Western Kenya. Completed NCT01166815 Phase 2, Phase 3
39 Double Blind, Randomized, Placebo Controlled Clinical Trial for the Treatment of Diabetic Foot Ulcers, Using a Nitric Oxide Releasing Patch: PATHON Completed NCT00428727 Phase 3 Controlled nitric oxide releasing patch;placebo patch
40 Oral Miltefosine Plus Topical Paromomycin In American Cutaneous Leishmaniasis Recruiting NCT03829917 Phase 2, Phase 3 Miltefosine and Paromomycin;miltefosine;paromomycin
41 An Open Label, Phase III, Randomized Controlled, Multicentre Non-Inferiority Trial to Compare Efficacy and Safety of Miltefosine and Paromomycin With SSG and PM Combination for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa Recruiting NCT03129646 Phase 3 Miltefosine;Paromomycin;Sodium stibogluconate
42 Phase III Clinical Trial for Mucosal or Mucocutaneous Leishmaniasis. Comparison Between the Standard and Alternative Antimonial Schemes Recruiting NCT01301937 Phase 2, Phase 3 Meglumine antimoniate
43 Miltefosine and GM-CSF in Cutaneous Leishmaniasis: a Randomized and Controlled Trial Not yet recruiting NCT03023111 Phase 3 Sbv;Miltefosine plus placebo;Miltefosine plus GM-CSF
44 Phase 3 Randomized Trial Comparing Fluconazole to Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis Caused by L. Braziliensis and L. Guyanensis Terminated NCT01953744 Phase 3 Fluconazole;Meglumine Antimoniate
45 Open Label Randomized Study to Assess Safety and Efficacy of Azithromycin Versus Meglumine Antimoniate to Treat Cutaneous Leishmaniasis Terminated NCT00682656 Phase 2, Phase 3 Glucantime®;Zithromax ®
46 Effectiveness, Safety and Feasibility of Thermotherapy With the Hand-held Exothermic Crystallization Thermotherapy for Cutaneous Leishmaniasis (HECT-CL), Device for Cutaneous Leishmaniasis in Quetta, Pakistan Terminated NCT03208543 Phase 3
47 Double Blind, Randomized Controlled Trial, to Evaluate the Effectiveness of a Controlled Nitric Oxide Releasing Patch Versus Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis Terminated NCT00317629 Phase 3 controlled nitric oxide releasing patch;meglumine antimoniate
48 Phase 2 Study of the Efficacy of Daylight Activated Photodynamic Therapy in the Treatment of Cutaneous Leishmaniasis Unknown status NCT00840359 Phase 2
49 EFFICACY AND SAFETY OF A SHORT COURSE OF THE COMBINATION OF MILTEFOSINE AND ANTIMONY TO TREAT CUTANEOUS LEISHMANIASIS IN BOLIVIA Unknown status NCT00537953 Phase 2 Miltefosine , meglumine antimoniate
50 A Prospective, Single Center, Open-Label, Dose-Escalation Phase II Study To Assess Safety and Efficacy Of Short-Course Regimens Of Amphotericin B Emulsion In Treatment Naïve Or Resistant Cases Of Visceral Leishmaniasis (Kala-Azar). Completed NCT00497601 Phase 2 Amphotericin B fat emulsion in visceral leishmaniasis;Amphotericin B fat emulsion;Amphotericin B in fat emulsion

Search NIH Clinical Center for Kala-Azar 1

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Antileishmanial [EPC]
Itraconazole
Ketoconazole
miltefosine

Genetic Tests for Kala-Azar 1

Anatomical Context for Kala-Azar 1

MalaCards organs/tissues related to Kala-Azar 1:

41
Testes, T Cells, Skin, Bone, Bone Marrow, Liver, Monocytes

Publications for Kala-Azar 1

Articles related to Kala-Azar 1:

(show top 50) (show all 20462)
# Title Authors PMID Year
1
Common variants in the HLA-DRB1-HLA-DQA1 HLA class II region are associated with susceptibility to visceral leishmaniasis. 38 8
23291585 2013
2
Genetic admixture in Brazilians exposed to infection with Leishmania chagasi. 38 8
19397557 2009
3
SLC11A1 (formerly NRAMP1) and susceptibility to visceral leishmaniasis in The Sudan. 38 8
14523377 2004
4
A major susceptibility locus on chromosome 22q12 plays a critical role in the control of kala-azar. 38 8
14557985 2003
5
Genetic control of visceral leishmaniasis in a Sudanese population: candidate gene testing indicates a linkage to the NRAMP1 region. 38 8
12618857 2003
6
The interplay between environmental and host factors during an outbreak of visceral leishmaniasis in eastern Sudan. 38 8
12475635 2002
7
Synthesis and biological evaluation of thiazole derivatives as LbSOD inhibitors. 38
30734600 2019
8
Appraisal of anti-protozoan activity of nitroaromatic benzenesulfonamides inhibiting carbonic anhydrases from Trypanosoma cruzi and Leishmania donovani. 38
31219348 2019
9
Biosynthesis of anti-leishmanial natural products in callus cultures of Artemisia scoparia. 38
30942629 2019
10
Dual and selective inhibitors of pteridine reductase 1 (PTR1) and dihydrofolate reductase-thymidylate synthase (DHFR-TS) from Leishmania chagasi. 38
31409157 2019
11
Leishmania infantum arginase: biochemical characterization and inhibition by naturally occurring phenolic substances. 38
31124384 2019
12
Treatment of resistant visceral leishmaniasis with interferon gamma in combination with liposomal amphotericin B and allopurinol. 38
31129197 2019
13
Effects of time-lagged meteorological variables on attributable risk of leishmaniasis in central region of Afghanistan. 38
31176974 2019
14
Evaluation of antileishmanial efficacy of Salidroside against the SSG-sensitive and resistant strain of Leishmania donovani. 38
31108221 2019
15
Space-time analysis of the incidence of human visceral leishmaniasis (VL) and prevalence of canine VL in a municipality of southeastern Brazil: Identification of priority areas for surveillance and control. 38
31233726 2019
16
Leishmania infection: Misdiagnosis as cancer and tumor-promoting potential. 38
30529443 2019
17
Expression, purification and spectrophotometric analysis of nucleoside hydrolase from Leishmania chagasi (LcNH). 38
31034876 2019
18
Phenylhydrazides as inhibitors of Leishmania amazonensis arginase and antileishmanial activity. 38
31311700 2019
19
Virtual and experimental screening of phenylfuranchalcones as potential anti-Leishmania candidates. 38
31252366 2019
20
Leishmania infantum induces expression of the negative regulatory checkpoint, CTLA-4, by human naïve CD8+ T cells. 38
31173374 2019
21
In vitro growth characteristics and morphological differentiation of Leishmania martiniquensis promastigotes in different culture media. 38
31132335 2019
22
Phlebotominae in peri-domestic and forest environments inhabited by Alouatta caraya in northeastern Argentina. 38
30895653 2019
23
A survey of sand flies (Diptera, Phlebotominae) along recurrent transit routes in Serbia. 38
31207207 2019
24
The impact of refugees on leishmaniasis in Turkey: a new Syrian/Turkish Leishmania tropica population structure described by multilocus microsatellite typing (MLMT). 38
31289943 2019
25
Paromomycin-loaded mannosylated chitosan nanoparticles: Synthesis, characterization and targeted drug delivery against leishmaniasis. 38
31300160 2019
26
Paromomycin-loaded mannosylated chitosan nanoparticles: Synthesis, characterization and targeted drug delivery against leishmaniasis. 38
31158341 2019
27
Functional aspects of T cell diversity in visceral leishmaniasis. 38
31195352 2019
28
Activated cytotoxic T cells within zoonotic cutaneous leishmaniasis lesions. 38
30997749 2019
29
Flavonoids induce cell death in Leishmania amazonensis: in vitro characterization by flow cytometry and Raman spectroscopy. 38
31360935 2019
30
Artemisinin-resistant Leishmania parasite modulates host cell defense mechanism and exhibits altered expression of unfolded protein response genes. 38
31359134 2019
31
Anti-Leishmania and cytotoxic activities of perillaldehyde epoxide synthetic positional isomers. 38
29533085 2019
32
Antileishmanial activity and immune modulatory effects of benzoxonium chloride and its entrapped forms in niosome on Leishmania tropica. 38
31406406 2019
33
The effect of pentavalent antimonial compounds used in the treatment of cutaneous leishmaniasis on hemogram and biochemical parameters. 38
31039622 2019
34
Chlorin, Phthalocyanine, and Porphyrin Types Derivatives in Phototreatment of Cutaneous Manifestations: A Review. 38
31398812 2019
35
Secondary Prophylaxis with Liposomal Amphotericin B in a Patient with Mucosal Leishmaniasis Undergoing Immunobiological Therapy for Active Ankylosing Spondylitis. 38
31219006 2019
36
A review of copper concentrations in Iranian populations. 38
31377885 2019
37
A comparative in silico analysis of Rab5 proteins from pathogenic species to find its role in the pathogenesis. 38
31432591 2019
38
[Pancytopenia of unknown origin in a 52-year-old patient]. 38
30969356 2019
39
Experimental infection of Phlebotomus perniciosus and Phlebotomus tobbi with different Leishmania tropica strains. 38
31401063 2019
40
The early-acting glycosome biogenic protein Pex3 is essential for trypanosome viability. 38
31341002 2019
41
Evaluation of antileishmanial drugs activities in an ex vivo model of leishmaniasis. 38
30991111 2019
42
Application of Dithiocarbamates as Potential New Antitrypanosomatids-Drugs: Approach Chemistry, Functional and Biological. 38
31374887 2019
43
In vitro activity and in vivo efficacy of fexinidazole against New World Leishmania species. 38
31049550 2019
44
Comparative Proteomic Analysis of Murine Cutaneous Lesions Induced by Leishmania amazonensis or Leishmania major. 38
31094195 2019
45
Global status of synchronizing Leishmania RNA virus in Leishmania parasites: A systematic review with meta-analysis. 38
31376334 2019
46
First Molecular Report of Leishmania (Leishmania) amazonensis and Leishmania (Viannia) guyanensis in Paraguayan Inhabitants Using High-Resolution Melt-PCR. 38
31407656 2019
47
The combination therapy of meglumine antimoniate and oxiranes (epoxy-α-lapachone and epoxymethyl-lawsone) enhance the leishmanicidal effect in mice infected by Leishmania (Leishmania) amazonensis. 38
31430693 2019
48
Development and evaluation of a loop-mediated isothermal amplification assay for rapid detection of Leishmania amazonensis in skin samples. 38
31150654 2019
49
Leishmania heme uptake involves LmFLVCRb, a novel porphyrin transporter essential for the parasite. 38
31372684 2019
50
Biological activity of Morita-Baylis-Hillman adduct homodimers in L. infantum and L. amazonensis: anti-Leishmania activity and cytotoxicity. 38
31392413 2019

Variations for Kala-Azar 1

Expression for Kala-Azar 1

Search GEO for disease gene expression data for Kala-Azar 1.

Pathways for Kala-Azar 1

GO Terms for Kala-Azar 1

Sources for Kala-Azar 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....